A Phase 3 interventional study of alendronate and Denosumab (AMG 162) in Postmenopausal Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2011-07-11.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 7th largest by enrollment, is one of 2 that started in 2006, is one of 17 in phase 3, and was the 4th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 504 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2006, is one of 14 in phase 3, and was the 4th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab. Endpoints studied will include bone mineral density, bone turnover markers and bone histology in a subset of subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Denosumab (AMG 162)
Drug: alendronate
70 mg oral QW
60 mg SC q 6 mos
Percent Change From Baseline in Total Hip Bone Mineral Density
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.
Time frame: Baseline, 12 months
Percent Change From Baseline in Lumbar Spine Bone Mineral Density
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.
Time frame: Baseline, 12 months
Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)
Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using \[(3 month value - baseline value) / baseline value\]\*100.
Time frame: Baseline, 3 months
First Subject Enrolled: 02-Oct-2006 Last Subject Enrolled: 07-Mar-2007
| Milestone | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Started | 251 | 253 |
| Received study medication | 249 | 253 |
| Completed | 238 | 243 |
| Not completed | 13 | 10 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Withdrawal by subject | 10 | 4 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.
| Percent Change | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Percent Change From Baseline in Total Hip Bone Mineral Density | 1.05 (0.76 to 1.34) | 1.9 (1.61 to 2.18) |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.
| Percent Change | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine Bone Mineral Density | 1.85 (1.44 to 2.26) | 3.03 (2.63 to 3.44) |
Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using \[(3 month value - baseline value) / baseline value\]\*100.
| Percent Change | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I) | -4.2 (-29.4 to 25.1) | -63.3 (-78.5 to -38.0) |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alendronate 70 mg QW | — | 16/249 (6.4%) | 101/249 (40.6%) |
| Denosumab 60 mg Q6M | — | 15/253 (5.9%) | 103/253 (40.7%) |
| Event | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| Tooth fractureInjury, poisoning and procedural complications | 2/249 | 0/253 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/249 | 0/253 |
| Angina pectorisCardiac disorders | 1/249 | 1/253 |
| Atrial fibrillationCardiac disorders | 1/249 | 0/253 |
| Appendicitis perforatedGastrointestinal disorders | 1/249 | 0/253 |
| Loose toothGastrointestinal disorders | 1/249 | 0/253 |
| NauseaGastrointestinal disorders | 1/249 | 0/253 |
| PancreatitisGastrointestinal disorders | 1/249 | 0/253 |
| VomitingGastrointestinal disorders | 1/249 | 0/253 |
| HyperpyrexiaGeneral disorders | 1/249 | 0/253 |
| Event | Alendronate 70 mg QW | Denosumab 60 mg Q6M |
|---|---|---|
| NasopharyngitisInfections and infestations | 27/249 | 34/253 |
| Back painMusculoskeletal and connective tissue disorders | 29/249 | 27/253 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 26/249 | 15/253 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 21/249 | 12/253 |
| BronchitisInfections and infestations | 14/249 | 16/253 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 13/249 | 11/253 |
| ConstipationGastrointestinal disorders | 12/249 | 13/253 |
| Age Continuous(Years) | Alendronate 70 mg QW | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Mean | 68.2 ± 7.7 | 66.9 ± 7.8 | 67.6 ± 7.8 |
| Sex: Female, Male(Participants) | Alendronate 70 mg QW | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| Female | 251 | 253 | 504 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Alendronate 70 mg QW | Denosumab 60 mg Q6M | Total |
|---|---|---|---|
| White or Caucasian | 232 | 238 | 470 |
| Black or African American | 2 | 0 | 2 |
| Hispanic or Latino | 12 | 11 | 23 |
| Asian | 1 | 1 | 2 |
| Japanese | 1 | 3 | 4 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
No study locations are listed for this record.
The record gives a start of Sep 2006, a primary completion of Mar 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 2 years 5 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →